An interventional study of New Abutment Connection implant and Nanotite Certain Tapered implant in Partial Edentulism and Tooth Disease, sponsored by ZimVie. Completed at 1 site in Chile. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-28.
Sponsored by ZimVie · Not applicable, Interventional, and Treatment
Integration success rates measured by lack of implant mobility and crestal bone regression measurement will be higher for the experimental implant design than for the control implants.
In this study patients are randomized to receive either the experimental implant system or the control Nanotite Certain Tapered (standard abutment connection) and assessed for integration success measured by cumulative success rate in cases that are loaded immediately
116 studies on the registry are indexed under Tooth Diseases; 14 are open to participants now.
This study's enrollment of 60 is above the median of 46 across 82 interventional studies indexed under Tooth Diseases.
Browse Tooth Diseases studies →ZimVie is the lead sponsor of 24 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Implant with new abutment connection
Device: New Abutment Connection implant
Nanotite Certain Tapered (standard abutment connection) implant
Device: Nanotite Certain Tapered implant
New abutment connection implant
Also known as: Osseotite Endosseous dental implant
Nanotite certain tapered (standard abutment connection) implant
Also known as: Nanotite Endosseous dental implant
Cumulative success rate
crestal bone regression (amount of bone loss measured) and equivalence in integration success (implant mobility)
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ZimVie